We focus on biomarker-driven research to deliver personalized treatments and a transformative, risk-balanced pipeline.
Translational research is embedded in the entire R&D process. With our innovative approach to treatment and novel combinations we address unmet needs in hard-to-treat cancers.
Our pipeline comprises high-quality, selective small molecules, antibodies and antibody-drug conjugates (ADCs). Strong translational research data supports each drug’s clinical development. All are clearly differentiated and have the potential to be best-in-class.
We focus on five innovation clusters:
- Oncogenic Signaling
- DNA Repair
- Tumor Metabolism
- Tumor Plasticity
Dedicated to delivering personalized medicine, we are aiming to identify patient populations likely to respond to treatment, guide optimal dosing through the use of pharmacodynamics biomarkers and thereby increase the probability of success in clinical development.
We believes that rational combinations are the key to the future of new and more efficacious treatment options. At our company, we are currently combining our targeted therapies with chemotherapy/radiotherapy, other targeted therapies and/or immunotherapies from our own, our partners’ and other external portfolios.
We recognize that no single organization can achieve these goals alone. We partner with leading academic institutions and innovative biotech innovators to complement our pipeline, strengthen our technology base and enhance our scientific capabilities.
Browse the programs in our pipeline to see what we’re currently working on by phase, therapeutic area, and compound type. You can also see what we’ve discovered in-house versus those assets we’re partnering on with other giants in our industry. Learn more